...
首页> 外文期刊>RSC Advances >Allosteric inhibition induces an open WPD-loop: a new avenue towards glioblastoma therapy
【24h】

Allosteric inhibition induces an open WPD-loop: a new avenue towards glioblastoma therapy

机译:变构抑制作用导致开放的WPD回路:成胶质细胞瘤治疗的新途径

获取原文

摘要

The mobility of loops around the catalytic site of a protein remains crucial to its activity. Dynamics of the WPD-loop is an essential determinant of the catalytic activity of tyrosine-protein phosphatase zeta, an implicated protein in glioblastoma cells. The WPD-loop assumes a closed conformation upon substrate binding in order to position its catalytic aspartate to participate in catalysis. Herein, we explore the impact of NAZ2329, a recently identified allosteric inhibitor of tyrosine-protein phosphatase zeta, on the atomic flexibility of the WPD-loop. The druglikeness of NAZ2329 was assessed using the SwissADME online tool. The enzymatic complex was then subjected to conformational simulations using the AMBER molecular dynamics software. Structural analysis revealed that NAZ2329 induced an open conformation of the crucial WPD-loop, consequently impeding enzyme activity even upon substrate binding. Based on the molecular interactions between NAZ2329 and tyrosine-protein phosphatase zeta, a pharmacophore model was generated to exhibit the important functional moieties of NAZ2329. These findings provide an insightful molecular and structural mechanism in targeting tyrosine-protein phosphatase zeta as a therapeutic intervention for glioblastoma. We believe that this optimized pharmacophoric model will aid in the design of improved anti-tyrosine phosphatase agents, thus allowing for increased patient adherence.
机译:蛋白质催化位点周围环的迁移性对其活性仍然至关重要。 WPD回路的动力学是酪氨酸蛋白磷酸酶zeta(胶质母细胞瘤细胞中的一种牵连蛋白)的催化活性的重要决定因素。 WPD环在与底物结合时采取闭合构象,以便定位其催化天冬氨酸以参与催化。在本文中,我们探讨了NAZ2329(最近发现的酪氨酸蛋白磷酸酶zeta的变构抑制剂)对WPD环原子柔性的影响。使用SwissADME在线工具评估了NAZ2329的药物相似性。然后使用AMBER分子动力学软件对酶复合物进行构象模拟。结构分析表明,NAZ2329诱导了关键WPD环的开放构象,因此即使在结合底物时也阻碍了酶的活性。基于NAZ2329与酪氨酸蛋白磷酸酶zeta之间的分子相互作用,生成了一个药效团模型以显示NAZ2329的重要功能部分。这些发现为靶向酪氨酸蛋白磷酸酶zeta作为胶质母细胞瘤的治疗手段提供了有见地的分子和结构机制。我们相信,这种优化的药效学模型将有助于设计改进的抗酪氨酸磷酸酶试剂,从而增加患者的依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号